Hims & Hers Health, INC Form 4 insider transactions

Hims & Hers Chief Commercial Officer Michael Chi reported a gift of Class A Common Stock and the exercise and sale of shares under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health, Inc. CFO Oluyemi Okupe sold 23,584 shares of Class A Common Stock for an average price of $57.7411 under a pre-arranged trading plan.

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, sold 2,637 shares of Class A Common Stock for $50.5 per share under a pre-arranged trading plan.

Hims & Hers Health, Inc. Chief Medical Officer Patrick Harrison Carroll sold 10,021 shares of Class A Common Stock for approximately $506,060.50 under a pre-arranged trading plan.

Hims & Hers Health, Inc.'s Principal Accounting Officer, Irene Becklund, sold 8,410 shares of Class A Common Stock for $50.5 per share under a pre-arranged trading plan.

Hims & Hers Health, Inc.'s Chief Commercial Officer, Michael Chi, sold 13,749 shares of Class A Common Stock for $50.5 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health, Inc. CEO Andrew Dudum sold 65,110 shares of Class A Common Stock for approximately $3.3 million under a pre-arranged 10b5-1 trading plan.

Hims & Hers Health, Inc. Chief Medical Officer Patrick Harrison Carroll reported routine transactions involving Class A Common Stock and Restricted Stock Units, including acquisitions and dispositions for tax obligations.

Hims & Hers Health's Chief Legal Officer, Soleil Boughton, reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Hims & Hers Health, Inc.'s Principal Accounting Officer, Irene Becklund, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations on September 15, 2025.

Hims & Hers Chief Commercial Officer Michael Chi executed stock options and vested restricted stock units, leading to both acquisitions and sales of Class A Common Stock on September 15, 2025, under a Rule 10b5-1 plan.

Hims & Hers Health, Inc. CEO Andrew Dudum reported significant sales of Class A Common Stock and exercise of stock options, primarily under a Rule 10b5-1 trading plan.

Hims & Hers Health, Inc. CFO Oluyemi Okupe executed a Rule 10b5-1 trading plan, involving the vesting of Restricted Stock Units, exercise of stock options, and subsequent sale of Class A Common Stock.

Kare Schultz, a Director at Hims & Hers Health, Inc., acquired 6,623 shares of Class A Common Stock through the vesting of Restricted Stock Units.

Hims & Hers Health, Inc.'s CFO, Oluyemi Okupe, exercised stock options and sold 11,581 shares of Class A Common Stock for an average price of $43.6895 per share.

Hims & Hers Health's Chief Legal Officer, Soleil Boughton, sold 2,571 shares of Class A Common Stock for $44.53 per share.

Hims & Hers Health, Inc. CEO Andrew Dudum executed pre-planned sales of Class A Common Stock totaling 175,661 shares, alongside exercising 125,335 stock options.

Hims & Hers Health, Inc.'s Chief Financial Officer, Oluyemi Okupe, exercised stock options and subsequently sold 11,581 shares of Class A Common Stock for approximately $48.05 per share.

Hims & Hers Chief Legal Officer Soleil Boughton sold 2,572 shares of Class A Common Stock for $51.64 per share under a Rule 10b5-1 plan.

Hims & Hers Health, Inc. CEO Andrew Dudum sold 660,000 shares of Class A Common Stock for approximately $33.4 million under a pre-arranged trading plan.

Hims & Hers Health, Inc. Director David B. Wells received a grant of 3,656 Restricted Stock Units, aligning his interests with long-term shareholder value.

Hims & Hers Health, Inc. director Christopher D. Payne was granted 3,656 Restricted Stock Units, aligning his interests with shareholders.

Hims & Hers Health, Inc. Director Andrea G. Perez Garcia was granted 3,656 Restricted Stock Units, aligning her interests with shareholders.

Hims & Hers Health, Inc. Director Delos M. Cosgrove was granted 3,656 Restricted Stock Units, vesting by mid-2026.

Hims & Hers Health, Inc. director Deborah M. Autor received a grant of 3,656 Restricted Stock Units (RSUs) as part of her compensation.

Hims & Hers Health, Inc.'s Chief Medical Officer, Patrick Harrison Carroll, reported a planned sale of 60,000 Class A Common Stock shares and the grant of 3,656 Restricted Stock Units.

Hims & Hers Health, Inc. Director Anja Manuel was granted 3,656 Restricted Stock Units, vesting by June 2026.

Hims & Hers Health, Inc. director Kare Schultz received a grant of 3,656 Restricted Stock Units, aligning interests with shareholders.

Hims & Hers Director Christiane Pendarvis receives 3,656 RSU grant.

Hims & Hers Health, Inc.'s Chief Commercial Officer, Michael Chi, executed stock options and sold a corresponding number of shares under a pre-arranged 10b5-1 trading plan.